Immunotherapy and systemic reactions

We read with interest the recent retrospective review by Winslow et al.1 The authors reported systemic reaction (SR) rates lower than those previously published.2 Of note, they use "standard build" for what is typically referred to as "conventional build-up". The advantage of reporting SR rates within a single large practice is the assumed consistency and standardization of immunotherapy delivery.

http://ift.tt/2vkljSd